ORLANDO, Fla. — The interleukin (IL)-4 and IL-13 inhibitor dupilumab improved itch symptoms and curtailed disease activity while also reducing oral corticosteroid use in older patients with bullous pemphigoid (BP), a phase 2/3 study demonstrated. “Dupilumab demonstrated significant benefits across multiple disease aspects in BP at 36 weeks, including achieving sustained remission at week 36 […]
The post Dupilumab Shown to Reduce Symptoms, Steroid Use in BP first appeared on News Health.
Author : News Health
Publish date : 2025-03-13 07:48:00
Copyright for syndicated content belongs to the linked Source.